Boston Scientific Sells Fluid Management, Venous Access Units
This article was originally published in The Gray Sheet
Executive Summary
Private equity firm Avista Capital Partners plans to operate Boston Scientific's combined fluid management and venous access units as a stand-alone company after acquiring the businesses for $425 million on Dec. 13
You may also be interested in...
AngioDynamics Doubles Vascular Access Biz With Navilyst Acquisition
Deal worth $372 million makes AngioDynamics the clear number-two competitor in the global vascular access market, second only to Bard.
Boston Scientific Spins Out TriVascular AAA Biz To Investors For $30 Mil.
Boston Scientific's reversal of its April 2005 acquisition of endovascular aortic aneurysm repair device developer TriVascular puts the newly independent entity back in the hands of its original management team in exchange for $30 million and a minority equity stake
Boston Scientific Spins Out TriVascular AAA Biz To Investors For $30 Mil.
Boston Scientific's reversal of its April 2005 acquisition of endovascular aortic aneurysm repair device developer TriVascular puts the newly independent entity back in the hands of its original management team in exchange for $30 million and a minority equity stake